SCHEMBL3918142

SCHEMBL3918142

O=C(NC12CC3CC(CC(C3)C1)C2)C1CCN(S(=O)(=O)CCN2CCCCC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.50
EPHX2 P34913 6/20 0.47
ALDH1A1 P00352 4/20 0.46
GAA P10253 1/20 0.41
EPHX1 P07099 4/20 0.41
CACNA1H O95180 1/20 0.41
TSHR P16473 3/20 0.40
RECQL P46063 1/20 0.40
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3928778 0.99 ALOX15 (0.51) ALOX15SMN1; SMN2EPHX2ALDH1A1GAA
SCHEMBL3918652 0.90 EPHX2 (0.47) ALOX15SMN1; SMN2EPHX2ALDH1A1EPHX1
SCHEMBL3918138 0.80 HSD11B1 (0.55) ALOX15SMN1; SMN2EPHX2ALDH1A1GAA
Hydrochloric Acid SCHEMBL3928772 0.79 HSD11B1 (0.53) ALOX15SMN1; SMN2EPHX2ALDH1A1GAA
SCHEMBL4516091 0.76 EPHX2 (0.67) SMN1; SMN2EPHX2ALDH1A1EPHX1TSHR
SCHEMBL14342610 0.74 ALOX15 (0.52) ALOX15SMN1; SMN2EPHX2ALDH1A1GAA
SCHEMBL3923879 0.73 EPHX2 (0.49) SMN1; SMN2EPHX2ALDH1A1GAAEPHX1
SCHEMBL4526450 0.73 EPHX2 (0.53) SMN1; SMN2EPHX2ALDH1A1EPHX1TSHR
SCHEMBL2638571 0.72 EPHX2 (0.59) EPHX2ALDH1A1EPHX1TSHRMEN1
SCHEMBL2638872 0.70 EPHX2 (0.57) EPHX2ALDH1A1EPHX1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US claimed
EP-2038255-A2 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES High Point Pharmaceuticals, LLC (US) 2009-03-25 EP claimed
WO-2007144394-A2 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC. (US) 2007-12-21 WO claimed
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-12-10 US disclosed
EP-2038255-A2 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES High Point Pharmaceuticals, LLC (US) 2009-03-25 EP disclosed
WO-2007144394-A2 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HIGH POINT PHARMACEUTICALS, LLC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306048-A1 PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES HSD11B1, HSD3B1, CES1 ALOX15 354/4885SMN1; SMN2 3206/4885EPHX2 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.